simple, robust and transgene-free technique to make "in vitro crosses" in hybrid mouse 26 embryonic stem cells by inducing random mitotic crossovers with the drug ML216, which inhibits 27
Bloom syndrome (BLM). Starting with an interspecific hybrid (between Mus musculus and Mus 28 spretus) embryonic stem cell line spanning 1.5 million years of divergence, we demonstrate the 29 feasibility of mapping enzymatic differences across species within weeks and the possibility of 30 re-deriving whole mice. Our work shows how in vitro crosses can overcome major bottlenecks 31 like hybrid sterility in traditional mouse breeding to address fundamental questions in 32 evolutionary biology. 33
Main Text: 34
Discovering the genetic changes underlying species differences is a central goal in 35 evolutionary genetic (1). However, hybrid crosses between even recently diverged species in 36 animals often suffer from hybrid sterility (1, 2), greatly complicating genetic mapping of trait 37 variation, especially in mammals. On the other hand, within-species genetic mapping has been 38 tremendously successful in linking genetic polymorphisms to trait variations in innumerable 39 organisms since the early twentieth century (3) (4) (5) . Almost all mapping studies across diverse 40 species have depended on meiotic linkage mapping panels generated through breeding to 41 identify genetic loci controlling trait variations, or quantitative trait loci (QTL). Mapping resolution 42 depends largely on crossovers arising from meiotic recombination to disentangle linked genetic 43 broad use in the mouse genetics community, albeit never explicitly in F1 hybrid ES cells with the 76 goal of genetic mapping. In 2004, two independent groups showed that recessive, biallelic 77 mutants could be reliably recovered in mouse ES cells without breeding by suppressing Bloom 78 Syndrome (BLM; Fig. 1a ) (16, 17) . Yusa and coworkers showed that these recessive mutants 79 arose via mitotic recombination between homologous chromosomes (18) . We reasoned that the 80 same mechanism could be leveraged to generate genome-wide random mitotic recombination. 81
This mechanism enabled the creation of panels of arbitrary size carrying recombinant genomes, 82 while avoiding the limitations of hybrid sterility or inbreeding depression (Fig. 1b) . 83 
[Main Text cont'd] 103
To test if BLM inhibition could lead to elevated homologous recombination rates in 104 mitosis, we inhibited BLM in a number of mouse ES cell lines using a recently discovered small 105 molecule inhibitor ML216 (Fig. 1c) (20) . As a first test, we started with F1 ES cells between two 106 laboratory mouse strains (C57BL/6J and 129, abbreviated to "BL6" and "129" here) that carried a 107 targeted transgene as a hemizygous allele at the GtRosa26 locus on distal Chromosome 6. We 108 estimated homologous recombination by counting colony survival under fialuridine (FIAU) 109 treatment, which selected against the transgene, which carried the dominant marker hygromycin 110 phosphotransferase-thymidine kinase (HyTK) and green fluorescent protein (GFP; Fig. 1-Figure  111 Supplement 1). We found that BLM inhibition led to highly elevated rates of homologous 112 recombination, as revealed by increased numbers of FIAU-resistant colonies ( Fig. 1c ; in vitro 113 recombination rate: 2.9×10 -4 per cell per generation) and the appearance of mosaic GFP 114 expression within a colony ( Fig. 2a, right panels) . This is broadly consistent with previously 115
reported rates under direct Blm suppression or disruption (targeted tetracycline inhibition or 116 knockout alleles: 2.3-4.2×10 -4 ; compared to wildtype rates between 8.5×10 -6 -2.3×10 -5 ) (16, 17) . 117
The small molecule BLM inhibitor ML216 offers unique experimental advantages, because its 118 application is simple, rapid and reversible, eliminating the use of transgenes for Blm disruption or 119 suppression (16, 17) or repeated transfections of small interfering RNA to achieve continued 120 suppression of Blm. Importantly, elevated homologous recombination under BLM inhibition is 121 9 genotypes telomeric to the breakpoint towards homozygosity (LOH, yellow to blue). (C) IVR also 140 occurred in cells carrying divergent genomes with no transgenes. (BL6 x CAST)F1 hybrid ES cells were 141 treated with ML216 and screened by PCR genotyping at diagnostic telomeric markers. Selected clones 142 (two recombinant and control clones each) were whole genome sequenced, showing recombination 143 events towards both homozygous genotypes, consistent with PCR genotype screening results (total 144 breakpoints per clone ranged from 0-2). Additional recombination events were also recovered, even 145 though the Chromosome 1 telomeric marker remained heterozygous (clone 54). These clones also 146 carried non-recombined chromosomes (e.g., Chromosome 6, fully heterozygous, yellow).
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To determine the frequency and distribution of mitotic crossovers under ML216-150 mediated BLM inhibition, we sequenced and compared the genomes of 11 clones that survived 151 ganciclovir selection (a FIAU alternative; Fig. 2b ). We also treated F1 hybrid ES cells derived 152 from BL6 and Mus castaneus (diverged ~1 million years ago; CAST/EiJ, abbreviated to CAST 153 here) (21) with ML216 but otherwise grown under non-selective conditions. Using the 154 transgene-free (BL6 x CAST)F1 line (21), we screened 46 randomly-picked ML216-treated 155 clones for spontaneous LOH recombinants and recovered recombinants in both directions on 156 Chromosome 1. Sequencing of specific recombinant clones revealed conversion from F1 157 heterozygous genotypes towards both BL6/BL6 and CAST/CAST homozygous genotypes at 158 the telomeres (Fig. 2c , clones 21 and 50, note also additional recombination on 159 Chromosome 13). In contrast, control non-recombinant clones retained heterozygosity at the 160 telomeres (clone 54 and 56). But even here we discovered a single clone carrying additional 161 internal recombinants on Chromosome 1 (Fig. 2c) . 162
Genome-wide sequencing of the recombinants revealed several striking patterns. First, 163 crossover breakpoints were distributed along the entire chromosome (e.g., Chromosome 6 in 164 Fig. 2b ), echoing previous reports in other , suggesting 165 recombinants can be used for mapping this as well as other cellular traits. Second, FIAU 166 selection strongly and significantly enriched for recombinant chromosomes compared to 167 unselected conditions (n=11 out of 11 vs. 9 out of 826; Fisher Exact Test, P < 2.2×10 -16 ), with the 168 recombination map biased strongly by the location of the selection cassette (all 11 crossovers 169 were centromeric to Chromosome 6, 113Mbp, Fig. 2b ). Our data suggest that chromosome 170 segments telomeric to the cassette did not affect selection and were free to recombine. This 171 observation, while relatively trivial for a targeted transgene here, was nonetheless instructive in mitotic recombination usually occurred only on one or few chromosomes at a time (Fig. 2b, c; , in stark contrast to an average of one crossover per chromosome 175 arm during meiosis. Importantly, our results are in broad agreement with other reports of 176 mitotic recombination (18, 22) . Taken together, the data show that BLM inhibition efficiently 177 generated in vitro recombination (IVR) across wide evolutionary distance and IVR ES cell panels 178 may constitute genetically distinct lineages ideal for genetic mapping. 179
Our experiments to determine IVR rate demonstrated that among the chromosome-wide 180 recombination positions their collective location and LOH state were indicative of the position 181 of the selectable transgene (HyTK or GFP), with the major difference being that under mitotic 182 recombination or IVR, the critical interval was defined only on the centromeric side. While it 183 would have been trivial to screen for additional lines to increase mapping resolution towards 184
GtRosa26, we chose to further illustrate the potential of this approach by mapping naturally-185 occurring variations using IVR. One classical polymorphism is the 25 to 75-fold increased 186 activity of the Mus spretus "a" allele of hypoxanthine-guanine phosphoribosyltransferase (Hprt a ) 187 compared to the laboratory mouse Hprt b allele (23). Importantly, HPRT metabolizes the anti-188 metabolite tioguanine (6-TG) and causes cytotoxicity. It should be noted that beside the known 189
Hprt polymorphism, tioguanine susceptibility itself has not been previously mapped genetically 190 within or between mouse species. Here, we expected ES cells carrying Hprt a to be highly 191 susceptible to 6-TG treatment, whereas Hprt b/b or Hprt -/-ES cells should survive far higher 6-TG 192 concentrations ( Fig. 3-Figure Supplement 1 ). We set out to map the QTL for differential 6-TG 193 susceptibility using a bulk segregant assay simply by comparing allele frequencies across the 194 genome between pools of 6-TG susceptible and resistant ES cells as determined by flow 195 cytometry. We called this procedure "flow mapping", which takes advantage of a structured 196 but genetically diverse population of cells in tissue culture (but also see "X-QTL" in yeast, 
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Allele frequencies were normalized against 6-TG R sample as an internal ML216 treatment control.
208
Plotted are per megabase mean SPRET allele frequencies ± s.e.m. after 5 d and 21 d ML216 treatment.
209
In both cases, the genome-wide peak window contains the Hprt gene with the SPRET allele showing significantly increased susceptibility. (C) Individual 6-TG R clones following 10 d ML216 treatment were 211 sequenced to determine recombination breakpoints. Crossovers in clones surviving 6-TG treatment 212 recombined significantly more likely in the SPRET-to-BL6 direction (S>B = 37; B>S = 5; P ≤ 2×10 -5 ) 213 between the centromere and Hprt, consistent with strong selection favouring the BL6 Hprt b allele. In 214 contrast, only 3 additional crossovers were detected telomeric to Hprt. At Hprt, most 6-TG surviving 215 clones are homozygous for the Hprt b allele (27 vs. 9 heterozygotes and 10 Hprt a homozygotes). mapping for 6-TG susceptibility clearly identified a single locus, providing strong evidence that 243 6-TG susceptibility depended only on Hprt genotypes. While flow mapping combined superior 244 mapping resolution and experimental simplicity as a bulk experiment, recovery of individual 245 clones could provide further proof through the recovery of specific recombination breakpoints 246 confirming the role of Hprt in mediating differential 6-TG susceptibility and exclusion of 247 alternative modes of resistance such as aneuploidy. To recover specific recombinant 248 breakpoints, we also sequenced 46 individual 6-TG R IVR clones after 10d ML216 treatment ( Fig.  249 3c). Echoing the skewed crossovers patterns centromeric to the HyTK selection cassette ( Fig.  250 2b), we observed more SPRET-to-BL6 than BL6-to-SPRET recombinants (35 vs. 8, P ≤ 2 × 10 -5 , 251 exact binomial test, h 1 ≥ h 0 ). We note, however, that despite the strongly skewed ratio of 27 252 BL6/BL6 homozygous clones at the Hprt locus out of 46 total recovered clones, we still 253 observed 9 heterozygotes and 10 SPRET/SPRET homozygous clones (BL6/BL6 58.6%; Chi-254 squared test using observed allele frequencies, ! 2 = 13.17, d.f. = 2, P ≤ 0.002). This could be 255 due to a quantitative, rather than absolute allelic difference in susceptibility to 25µM 6-TG 256 treatment ( Fig or other new mutation(s) at Hprt or elsewhere leading to 6-TG resistance (16). Taken together, 258 we conclude that we were able to perform forward genetic mapping using IVR and recover Hprt 259 as the gene underlying 6-TG susceptibility differences between BL6 and SPRET. 260 262 263 defects. Besides major developmental defects, we also identified and obtain 3D 295 measurements from specific organs, including sub-regions of the brain, the heart and the liver, in multiple individuals from each ES cell line. Given an expanded panel of IVR ES lines, this 297 approach illustrates the potential of characterizing, or even mapping, the genetic basis of 298 evolutionary developmental variation. Despite the small sample size, our results show for the 299 first time the feasibility and exciting opportunity to quantify and genetically map variation in 300 developmental phenotypes in mammals using recombinants from evolutionarily divergent 301
species. 302
A central goal of evolutionary genetics is to identify how mutations arose during 303 evolution and influenced phenotypes. For many organisms, a major barrier has been the 304 inability to reliably generate diverse and large mapping panels of sufficient evolutionary diversity. 305
Here we describe a simple and robust method to make "in vitro crosses", resulting in 306 functionally intercross panels from otherwise sterile interspecific hybrid crosses. Being able to 307 bring forth genetic diversity in a petri dish creates the unique opportunity to conduct mouse 308 genetic mapping at unprecedented speeds with "flow mapping" (similar to "X-QTL" in yeast) 309 (24) or arbitrarily large panels unmatched by most other model organisms, except possibly 310 yeast (22, 24) . As indefinitely renewable stem cell lines, IVR panels can be expanded, archived 311 and shared, offering an arguably more feasible and cost-effective platform with many of the 312 advantages sought from traditional community resources such as recombinant inbred line 313 panels. Recently, Sadhu and coworkers have also achieved a major advance in genetic 314 mapping using CRISPR/Cas9-mediated mitotic recombination in yeast (22). In contrast to 315 CRISPR targeting, our transgene-free approach offers the simplicity of inducing genome-wide 316 recombinants by the simple addition of a single inexpensive small molecule to the tissue culture 317 medium. Further, we have shown that our IVR method works in a broad range of ES cells. 318
With millions of potentially recombinant (thus genetically distinct) ES cells in a petri dish, we 319 demonstrated how IVR enabled us to map a QTL for drug resistance in as few as 6 days (with 320 an estimated total of 5 doublings over 5 days under ML216 treatment). Putting this in context, such an experiment using traditional mouse crosses would have taken 450 days, based on the 322 typical mouse generation time of 90 days, assuming that hybrid sterility could be overcome and 323 allowing for selfing. Going forward, we envision a combined, complementary approach to IVR: 324 using BLM inhibition for mapping panel generations and efficient QTL identification, then 325 switching to targeted transgene-based screening or CRISPR/Cas9-based IVR for fine-scale 326 mapping. 327
As a novel mapping system, we observed a number of key differences between IVR and 328 conventional meiotic genetic mapping. First, loss-of-heterozygosity due to mitotic 329 recombination tend to occur between the breakpoint and the telomeres. Unlike conventional 330 breeding with random assortment, under IVR in F1 hybrids, outcrosses are not possible. As a 331 result, we tend to observe only heterozygous genotypes near the centromere, with informative 332 crossovers almost always found between the centromere and a selectable QTL but not on the 333 telomeric side. This asymmetry often led to a plateau in the association profiles from the QTL 334 towards the telomeres on a given chromosome ( Fig. 2b and 3c) , an effect also seen in (22). As 335 a consequence, interval mapping in IVR analogous to those in meiotic panels yields excellent 336 genetic resolution on the centromeric side but poor resolution on the telomeric side [see 337 distribution of crossover directions and breakpoints in Fig. 3c and (22)]. Second, access to 338 common tissue culture methods under IVR greatly mitigates typical concerns such as panel 339 sizes and power calculation in generating meiotic mapping panels. Since it is trivial to freeze 340 samples and introduce selectable markers at any given locus or targeted chromosome breaks 341 with a Crispr/Cas9 panel (22) with ES cells under tissue culture conditions, refinement of 342 mapping resolution under IVR no longer depends on the diminishing return of breeding and 343 screening for increasingly rare informative recombinants. To underscore this point, our flow 344 mapping experiment for 6-TG susceptibility achieved mapping resolutions within 10 Mbp within 345 weeks. Third, while it is true that mitotic recombination as used in IVR depends on error-prone repair of double-strand breaks that could affect phenotype through chromosome 347 rearrangements and new mutations at breakpoints, two observations from our results may 348 moderate this concern. One, we did not observe elevated aneuploidy under ML216 treatment, 349 suggesting that IVR did not elevate rates of chromosome rearrangements ( Fig. 1-Figure  350 Supplement 2). Two, millions of variants already exist in our (BL6 x CAST) F1 or 351
(BL6 x SPRET) F1 lines. These variants vastly outnumber any new mutations generated 352 through IVR. Assuming a typical spectrum of mutation effects, these parental variants likely 353 would contribute far more to trait variance than new mutations arising in a specific line. Since 354 genetic mapping depends on testing for different genotypic effect of an allele across all lines 355 carrying the same genotype at loci that are typically megabases away from a random double-356 strand breakpoint, it is reasonable to expect that the mutagenic effect of mitotic recombination 357 should have a rather limited impact on genetic mapping. Under the flow mapping design, the 358 mutagenic effect of mitotic recombination is further diluted, because millions, if not tens of 359 millions of cells in bulk population cultures are phenotyped and sequenced as pools. This 360 conclusion is supported by our ability to locate and map various transgenes or QTLs in this 361 current study. We are nonetheless in the process to formally characterize the relative 362 contribution to trait variation due to the mutagenic effects of IVR and that of the parental 363 genomes. 364
Rather than thinking of IVR as a replacement of current genetic mapping methods, we 365 see its establishment as an important extension to the existing toolkit that is complementary to 366 whole organism methods. In the mouse, the largest organismal recombinant inbred (RI) panel 367 BXD contains "only" ~160 lines (with most published work based on the ~35 original BXD 368 strains)(29) and attempts in generating panels incorporating greater divergences encountered 369 enormous challenges (30). Nevertheless, mouse RI resources still represented some of the model organism (31). Seen in this light, the mouse community should encourage alternative 372 approaches that could greatly extend the available renewable resources, even in a cellular or 373 tissue context, not least because the genotype combinations between divergent species would 374 have been hitherto impossible to obtain in the first place. 375
Given its potential for broad applications, we are currently making improvements to 376 many aspects of in vitro recombination to make trait mapping of interspecific differences in 377 mouse or other mammals routine. This includes improving the efficiency of IVR panel creation 378 from hybrid cell lines and developing robust phenotyping protocols beyond the proof-of-379 concept experiments we have presented here. For example, we have already made 380 refinements in IVR to screen for lines carrying recombination on multiple chromosomes (to be 381 published separately). We are also performing detailed characterization on the location and 382 distribution of recombination breakpoints to determine if certain genome features promote 383 mitotic recombination (see possibly clustered breakpoints in Fig. 2b & 3c) . In addition to the 384 traits we have investigated, Mus spretus and the Mus musculus laboratory mouse differ in a 385 number of distinct traits. Comprehensive genetic dissection of traits such as longevity and 386 telomere lengths (32), cancer and inflammation resistance (33, 34) and metabolism (35), would 387 be extremely useful. Many of these traits have tissue or cellular models that can be used in the 388 context of IVR. For cellular traits that can be measured as fluorescent signals, either from 389 immunohistochemistry staining of marker proteins or antigens, flow mapping would be readily 390 applicable. Especially in the area of stem cell biology and genome functional genomics, the 391 IVR platform opens up entire new possibilities for exploring how evolutionary divergence affects 392 genome functions through expression QTL mapping, ChIP or ATAC-Seq and where applicable, 393 flow mapping (and further fine mapping using Crispr-directed recombination as appropriate). 394
At this stage, testing of specific genes discovered through the process via knock-in gene 395 replacement as whole mice would serve as validation of the in vitro findings. For derivation of whole mice from IVR lines, we acknowledge that our immediate attempt serves only to illustrate 397 the possibility of obtaining whole animals from IVR genotypes, rather than a full-scale attempt 398 at mapping developmental differences. It is important to stress that actual genetic mapping of 399 developmental differences will require a much greater number of lines, ideally using improved, 400 highly-recombinant IVR methods. Clearly, such a study will represent a major undertaking for 401 single laboratories or small consortia. However, against the backdrop of systematic 402 phenotyping performed on hundreds of lines in the mouse knock-out consortium, the costs and 403 effort in screening a number of lines comparable to RI panels (around 35 lines) using IVR would 404 not only be feasible, but also very likely to produce important results because it covers great 405 evolutionary distances. 406
Future experiments may also probe even greater evolutionary divergence: early work 407 has shown that F1 hybrids spanning as much as 6 million years between Mus musculus and 408
Mus caroli was viable (36); or even human-mouse trans-chromosomal lines like Tc1 (37). 409 Further, given active development in single-cell genomics and disease modeling from patient-410 specific induced pluripotent stem cells (iPSC), especially with organoids or organ-on-a-chip 411 microfluidics systems, we are optimistic that the in vitro recombinant platform can be broadly 412 applied to mouse, human or even other species to accelerate the identification of the genetic 413 basis of many traits and diseases. 414 
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Fluorescence-Activated Cell Sorting (FACS) 
726
Flow cytometry was performed at the University Clinic Tübingen Dermatology Clinic FACS Core Facility 727 using an Aria II Cell Sorter (Becton Dickinson GmbH, Heidelberg, Germany). To determine cell viability, 728 we performed the DAPI exclusion assay. After excluding cell aggregates, we defined the 6-TG R and 6-729 TG S populations using conservative interval gates based on evaluating the data from reference flow 730 experiments with 6-TG-treated DAPI-stained ES cells. For cell population evaluations, flow cytometry 731 data was exported from BD FACSDiva Software v8.0.1 (Becton Dickinson). We carried out basic 732 data handling and log 10 transformation using the R Bioconductor package flowCore (45). Since live 733 and dead cells cluster also in other measurements, we took both forward scatter area (FSC-A) and DAPI 734 into account for our quantification, rather than using a simple interval gate on the DAPI/Pacific Blue-A 735 channel. We defined data-driven "Live" and "Dead" clusters using mclust v5.2 (46, 47) in 6-TG-736 treated experiments, considering ML216-treated and controls separately. We then classified each cell in 737 to the "Live" and "Dead" clusters, applying a 5% uncertainty cut-off. "Live" and "Dead" proportions 738 were then calculated from the confidently assigned cells. Data was visualized using the package 739 flowViz (48) (Fig. 3-Figure Supplement 
794
Coverage depths for the reference and alternative alleles were calculated based on the DP4 field in the 795 variant VCF files. For individual clones, crossover breakpoints were called by TIGER (61), using default 796 parameters. Custom Perl scripts were used to process files prior to plotting and visualization in R.
797
Scripts are available upon request.
799
Laser-assisted morula injection 800 Fully ES cell-derived embryos were obtained essentially as previously described in (27) . Briefly, female 801 C57BL/6NCrl mice were mated and host embryos harvested. ES cells from untreated S18 line and two 802 IVR lines were injected into 8-cell stage embryos (morulae) after perforation of the zona pellucida with a 803 laser pulse. After incubation for 1.5-2 h, injected embryos were transferred into the oviducts of E0.5 
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Optimal 6-TG concentration for differential Hprt-dependent cytotoxicity. 
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844
Recombinant genomes of the two S18 IVR ES cell lines selected for embryo re-derivation. Figure modified from (39 
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903
Whole embryos derived from laser-assisted morulae injection results showed that the S18 line, and IVR 904 lines 1 and 2 are broadly competent to differentiate into diverse cell lineages (Fig. 4, Fig. 4 Table S1 ). Amplified fragment sizes were determined using a capillary sequencer. The 948 markers were designed such that they show staggered fragment sizes, allowing clear identification using 949 fragment analysis software. Shown above are the electropherogram traces corresponding to the clones 950 shown in Fig. 2, out 
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Under ML216 treatment alone, cells show robust viability (second column). Only after 1 d 6-TG 997 treatment do the cells exhibit greatly increased cell death, as shown by the increased proportion of the 998 "Dead" population (third column; red). Notably, combined ML216 and 6-TG treatment appears to 999 mitigate cell damage and death, as indicated by the increased proportion of the "Live" population (third
